MedTrace Logo

Effect of Cladribine Treatment on Microglial Activation in the CNS

NCT04239820 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 15

Last updated 2025-01-15

No results posted yet for this study

Summary

To evaluate the effect of cladribine treatment on microglial activation with conventional MRI, QSM-post processing and TSPO-PET imaging in late stage relapsing remitting multiple sclerosis patients.

Conditions

Interventions

RADIATION

Imaging

MRI and TSPO-PET imaging at baseline and 18 months after baseline

Sponsors & Collaborators

  • Turku University Hospital

    lead OTHER_GOV

Principal Investigators

  • Laura Airas, Professor · Turku University Hospital, division of clinical neurosciences

Eligibility

Min Age
45 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-10
Primary Completion
2024-02-15
Completion
2025-12-31

Countries

  • Finland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04239820 on ClinicalTrials.gov